系统性硬化症下尿路症状的详细研究
本研究通过自报问卷比较42例系统性硬化症(SSc)患者与50名匹配健康对照的下尿路症状(LUTS),发现SSc患者尿失禁(UI)和膀胱过度活动症(OAB)的患病率及严重程度显著更高,且SSc是LUTS的强预测因素(OR 5.57,95%CI 1.64-18.88)。在SSc患者中,OAB与肌少症、UI与Scl70抗体及环孢素治疗正相关,与RNA聚合酶III抗体负相关,OAB与钙质沉着正相关、与甲氨蝶呤治疗负相关。
要点
- SSc患者UI和OAB患病率及严重度显著高于健康对照。
- SSc是LUTS的独立强预测因素(OR 5.57,95%CI 1.64-18.88)。
- OAB与肌少症、钙质沉着正相关,UI与Scl70抗体及环孢素正相关。
核心结论
- SSc患者尿路受累(UI和OAB)显著高于匹配健康对照,且肌少症、骨损害和钙质沉着与LUTS显著相关,提示可能存在相互作用。
研究设计与样本
- 通过自报问卷评估42例SSc患者和50名匹配健康受试者的下尿路症状(LUTS),并分析其与SSc变量(包括甲襞视频毛细血管镜模式、SSc相关抗体和DXA参数)的关联。
主要发现
- SSc患者UI和OAB的患病率及严重程度显著高于健康对照(P < 0.005,P < 0.01)。
- SSc是LUTS的强预测因素,独立于人口学数据、合并症和治疗(OR 5.57,95%CI 1.64-18.88)。
- SSc患者中OAB与肌少症正相关(P < 0.001),OAB和UI均与骨密度降低显著相关(P < 0.05,P = 0.001)。
- UI与Scl70抗体正相关(P < 0.05)、与环孢素治疗正相关(P = 0.001)、与RNA聚合酶III抗体负相关(P < 0.05);OAB与钙质沉着正相关(P < 0.005)、与甲氨蝶呤治疗负相关(P < 0.05)。
- 甲襞视频毛细血管镜「active」和「late」模式在出现泌尿症状的SSc患者中占主导,但无统计学相关性。
临床怎么用
- 对SSc患者应主动询问下尿路症状,尤其关注尿失禁和膀胱过度活动症。
- SSc患者出现LUTS时,需评估肌少症、骨密度及钙质沉着等并存问题。
局限性
- 样本量较小(42例SSc患者和50名健康对照),部分关联可能受限于统计效能。
- LUTS通过自报问卷评估,可能存在报告偏倚。
- 横断面设计无法推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Urinary tract involvement is a seldom-reported manifestation of SSc that could compromise patients' quality of life. This study compares lower urinary tract symptoms (LUTS) in SSc patients and in healthy subjects and their association with clinical and diagnostic parameters. METHODS: LUTS were assessed through self-reported questionnaires in 42 SSc patients and 50 matched healthy subjects. Statistical analyses were performed to explore LUTS in the two populations and their association with SSc variables, including nailfold videocapillaroscopy patterns, SSc-related antibodies and DXA parameters. RESULTS: SSc patients showed significantly higher prevalence and severity of urinary incontinence (UI) and overactive bladder (OAB) than healthy controls (P < 0.005, P < 0.01). SSc was a strong predictor of LUTS, independent of demographic data, comorbidities and treatments (odds ratio 5.57, 95% CI 1.64-18.88). In SSc patients OAB positively correlated with sarcopenia (P < 0.001), and both OAB and UI significantly correlated with reduced BMD (P < 0.05, P = 0.001). UI positively correlated with Scl70 antibodies (P < 0.05) and ciclosporin treatment (P = 0.001) and negatively with RNA polymerase III antibodies (P < 0.05); OAB positively correlated with calcinosis (P < 0.005) and negatively with methotrexate treatment (P < 0.05). Nailfold videocapillaroscopy 'active' and 'late' patterns were predominant among SSc patients presenting urinary symptoms, although no statistical correlation was found. CONCLUSION: For the first time urinary tract involvement was found to be significantly higher in SSc patients than in healthy matched controls. In addition, sarcopenia, bone damage and calcinosis appeared significantly correlated with LUTS, suggesting a possible interplay.
引用
- Pacini G, Paolino S, C Trombetta A, et al. Lower urinary tract symptoms in systemic sclerosis: a detailed investigation. Rheumatology (Oxford). 2020. PMID: 31586421. doi:10.1093/rheumatology/kez438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。